924ccfdb-f369-4b69-a034-bfbaf0878842
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.400
- ALLOGRAFT_REJECTION+0.300
- G2M_CHECKPOINT+0.200
- HEDGEHOG_SIGNALING+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- MYC_TARGETS_V1+0.200
- MYC_TARGETS_V2+0.200
- NOTCH_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.200
- UV_RESPONSE_DN+0.200
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- ADIPOGENESIS-0.300
- ANGIOGENESIS-0.300
- BILE_ACID_METABOLISM-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- COAGULATION-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- FATTY_ACID_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AE6Y-TTP1-A-1-0-R-A741-41 | — | D | 0.839 |
| 2 | AUR-AFEA-TTM6-A-1-0-R-A741-41 | — | D | 0.789 |
| 3 | TCGA-D8-A147-01A-11R-A115-07 | — | E | 0.760 |
| 4 | AUR-AG0N-TTP1-A-1-0-R-A741-41 | — | D | 0.754 |
| 5 | SRR15030894 | — | — | 0.753 |
| 6 | 73f8f4d0-1a2a-44ae-9e99-be730660d7c7 | — | — | 0.749 |
| 7 | 550c15f6-55cf-4928-bc62-bb28bc5672da | — | — | 0.735 |
| 8 | SRR650203 | — | — | 0.725 |
| 9 | TCGA-96-A4JL-01A-11R-A24Z-07 | — | cohortSQ1 | 0.723 |
| 10 | 0f095e03-de38-4be9-874c-c58893e031d9 | — | — | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |